An Assessment of the Apex Microarray Technology in Genotyping Patients with Leber Congenital Amaurosis and Early-Onset Severe Retinal Dystrophy by Henderson, Robert H. et al.
An Assessment of the Apex Microarray Technology in
Genotyping Patients with Leber Congenital Amaurosis
and Early-Onset Severe Retinal Dystrophy
Robert H. Henderson,1,2,3 Naushin Waseem,2 Rowan Searle,2 Jacqueline van der Spuy,2
Isabelle Russell-Eggitt,3 Shomi S. Bhattacharya,2 Dorothy A. Thompson,3
Graham E. Holder,1 Michael E. Cheetham,2 Andrew R. Webster,1,2 and
Anthony T. Moore1,2,3
PURPOSE. Leber congenital amaurosis (LCA) and early-onset
severe retinal dystrophy (EOSRD) are genetically heteroge-
neous, with 11 genes currently implicated. The LCA chip may
be used to interrogate many variants in one hybridization
reaction. The purpose of this study was to assess the utility of
this technology.
METHODS. One hundred fifty-three patients with LCA and
EOSRD were screened using an array (Asper Ophthalmics,
Tartu, Estonia) containing 344 published disease-causing vari-
ants and polymorphisms in eight genes: AIPL1, GUCY2D,
CRB1, CRX, RPGRIP1, RPE65, MERTK, and LRAT. One hun-
dred thirty-six probands underwent bidirectional sequencing
of the full coding region of the RPE65 gene. The same tech-
nique was also used to confirm CRB1 and AIPL1 mutations
initially identified with the Apex chip (Asper Ophthalmics).
Single nucleotide polymorphism (SNP) analysis within control
populations was performed for two variants, P701S and W21R,
on the chip for GUCY2D.
RESULTS. Of the possible 109,392 interrogations, 3,346 (3.06%)
failed on one strand whereas 259 (0.47%) failed on both. The
chip reported mutations in 68 (44%) patients; 26 patients had
two alleles identified (17%). Direct sequencing of RPE65
showed no discrepancies, whereas sequencing of AIPL1 and
CRB1 revealed seven samples called erroneously. The SNP
analysis of both GUCY2D variants revealed equal prevalence in
the EOSRD panel and the normal population. Subsequent re-
analysis, after excluding these polymorphisms, revealed one
(18.3%) or two (11.7%) mutations identified in 46 patients.
When evaluated by diagnosis, 46% of patients with LCA had
one or two mutations identified, compared with 24% of pa-
tients with EOSRD.
CONCLUSIONS. This approach is a rapid and reasonably low-cost
technique for identifying both previously identified mutations
and common polymorphisms. The addition of further genes
and mutations to the chip will improve its utility, though it is
advised that all results be checked by direct sequencing. (In-
vest Ophthalmol Vis Sci. 2007;48:5684–5689) DOI:10.1167/
iovs.07-0207
L eber’s congenital amaurosis (LCA) is a severe rod–conedystrophy that is symptomatic from early infancy; it is
clinically and genetically heterogeneous.1,2 LCA is usually in-
herited as an autosomal recessive trait, but rare autosomal
dominant forms have been reported.3 To date, 11 genes have
been implicated in LCA and it is evident that mutations in some
of them give rise to a different clinical phenotype with onset of
symptoms in early childhood and better initial visual function:
this group of disorders may be better termed early-onset severe
retinal dystrophy (EOSRD).
Several different genes, including GUCY2D,4 AIPL1,5
RPE65,6,7 RPGRIP1,8,9 CRX,10,11 TULP1,12,13 CRB1,14 RDH12,15,16
LRAT,17 MERTK,18 and, most recently, CEP290,19 have been
implicated in LCA and EOSRD but these account for only
approximately 55% to 65% of patients,1,2,19,20 and more genes
remain to be discovered. Molecular diagnosis in EOSRD and
LCA is problematic, given the large number of genes; screening
of 142 exons in 11 genes is labor intensive and expensive. The
development of parallel genotyping technologies (the Af-
fymetrix array; Affymetrix, Santa, Clara, CA; Illumina platform;
Illumina, San Diego, CA; or the Apex chip; Asper Ophthalmics,
Ltd., Tartu, Estonia) provide an opportunity for simplifying
molecular diagnosis in such disorders.
One such technology, the Apex chip (Arrayed Primer Ex-
tension; Asper Ophthalmics, Ltd.), was first described in 1996
as a novel method for DNA analysis.21,22 It was designed for
LCA23 as a microarray which, at the time of this study, con-
tained 344 disease-associated SNPs and several common variant
polymorphisms in six LCA- and two EOSRD-associated genes
(GUCY2D, CRX, RPE65, CRB1, RPGRIP1, AIPL1, LRAT, and
MERTK). More recently, mutations in two additional genes
RDH12 and CEP290 have been added to the chip. The PCR
products for each amplimer are combined and, in a single
hybridization reaction, are annealed to oligonucleotide primers
arrayed on the chip. A template-dependent single-nucleotide
extension reaction follows, with DNA polymerase and four
fluorescently labeled dye terminator nucleotides. These detect
variation at the site in question for both sense and antisense
strand, with Genorama genotyping software (Asper Ophthal-
mics, Ltd.).
In the present study, the efficacy of the LCA Apex chip
(Asper Ophthalmics, Ltd.) was investigated in 153 probands
with LCA/EOSRD and, in the case of AIPL1, CRB1, and RPE65,
the results were compared with direct sequencing, the ac-
cepted and historic gold standard.
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METHODS
Study Subjects
One hundred fifty-three unrelated individuals with diagnosed LCA/
EOSRD took part in the study. Patients were eligible for the study if
they had a clinical diagnosis of LCA or if they had a severe retinal
dystrophy that was symptomatic before the age of 5 years with an
absent or severely attenuated electroretinogram at diagnosis. Patients
with associated systemic disease or family history suggestive of auto-
somal dominant or X-linked recessive disease were excluded.
Research procedures were in accordance with institutional guide-
lines and the Declaration of Helsinki. Ethics committee approval was
obtained. All patients and parents were provided with information
sheets before informed consent was obtained.
More than 90% of the patients were examined by two ophthalmol-
ogists (RHH, ATM) at Moorfields Eye Hospital. For the remaining
patients, the clinical details were retrieved from the medical records.
All patients had diagnoses based on history, clinical appearance, and
results of electroretinography. DNA was extracted from whole blood
obtained from each affected individual.
In six very young individuals, repeated buccal samples and whole
genome amplification (Geneservice Ltd., Cambridge, UK) did not yield
DNA of sufficient quality for reliable genotyping. In those cases, pa-
rental DNA was used across the chip.
In addition, an SNP assay for two particular variants—the
c.2101CT p.P701S and c.61TC p.W21R changes in GUCY2D—was
performed in unaffected control DNA samples. The P701S change has
been discussed in the literature and described by some as disease-
causing in certain populations.23 It is listed on the HGMD (Human
Gene Mutation Database; http://www.hgmd.cf.ac.uk/ provided to reg-
istered users only) database as a disease associated missense mutation
despite evidence that the variant is present within the normal popu-
lation.24 The W21R change is listed on the chip as a disease-associated
mutation, though it has also been found in normal populations previ-
ously.24 No mention of the P701S GUCY2D variant is made by Yzer et
al.25 Whether this is because it had been discounted as a polymorphism
or it was not found in the 58 northern European patients with LCA is
not known.
Molecular Methods
Apex Chip. Concentrated DNA (3.5 g), from 147 unrelated
affected patients and 12 unaffected parents of probands, was sent to
Asper Ophthalmics, Ltd. The technology and methods used have been
described elsewhere.26
RPE65, CRB1, and AIPL1 Sequencing. Each of the 14
exons of RPE65, 18 amplimers for 12 exons of CRB1, and 6 exons of
AIPL1 were amplified (Extensor Hi-Fidelity PCR Master Mix; ABgene,
Epsom, UK). Primers for RPE65 were described by Marlhens et al.6
Primers for CRB1 and AIPL1were created to cover the exon and splice
site junctions and were designed using Primer 3 (http://frodo.wi.mit.
edu/cgi-bin/primer3/primer3_www.cgi/ provided in the public do-
main by the Whitehead Institute, Massachusetts Institute of Technol-
ogy, Cambridge, MA) and ordered from Sigma-Genosys (Poole, UK).
The amplified products were sequenced with dye termination chem-
istry (Big Dye Terminator cycle kits, ver. 1.1; Applied Biosystems, Inc.,
Warrington, UK) according to the manufacturer’s instructions.
K-Bio SNP Assay. A 50-bp sequence either side of the
c.2101CT p.P701S change in GUCY2Dwas supplied in a spreadsheet
format (Excel; Microsoft Inc., Redmond, WA) to KBiosciences (Hod-
desdon UK). Oligonucleotide primers were subsequently designed and
tested using two heterozygous control samples as identified by the LCA
chip. KBiosciences currently uses an in-house chemistry process (KAS-
Par), to perform their SNP genotyping. This process is a homogenous
fluorescence resonance energy transfer (FRET)–based, allele-specific
PCR on which the patent is pending. Once validated, the assay was
then run on two 96-well plates of ECACC (European Collection of Cell
Cultures; British blood donor) control DNA samples.
The c.61TC p.W21R change in GUCY2D was assayed using a
restriction digest (HinpII) in two control populations: 96 ECACC
control and 60 Asian control subjects. Exon 2 of GUCY2D was ampli-
fied in the control DNA samples by using primers designed in Primer
3. A 20-L reaction volume composed of PCR master mix (Hi-Fidelity;
ABgene) was run at 57°. Ten microliters of the PCR product was
incubated with 2 units of HinpII overnight at 37°C. Eight microliters of
the digest was then run on a 3% agarose gel with a PhiX ladder (Fig. 1).
RESULTS
Patient Cohort
One hundred fifty-three patients were recruited (90 male, 63
female; one-tailed Fisher exact test; P  0.06). Of the entire
cohort, 58% were white British subjects; 16% were of other
white backgrounds, mostly European; and 20% were of Asian
extraction, mostly Pakistani (12%) or Indian (5%). Twenty-one
percent of the patients were products of consanguineous mar-
riages. The mean age at diagnosis was 3.5  4 years (SD), and
the mean age at onset of symptoms was 1.8  3 years. Fifty-
nine patients had a diagnosis of LCA, whereas the remaining 94
patients had a diagnosis of either early-onset rod–cone or
cone–rod dystrophy (Table 1).
LCA Chip Results
Disease-associated variants, called by Asper Ophthalmics as
mutations, were identified in 68 individuals (44%). Homozy-
gous (n  9) or compound heterozygous mutations were
found in 25 (17%) patients, and a further 43 (28%) patients had
a single mutation identified (Table 2).
Two heterozygous mutations within two separate genes
were seen in seven samples, though four of these were subse-
quently discounted as polymorphisms. Of the 12 parental DNA
samples that were used, changes were identified in 5 (Table 3).
One of these was the AIPL1 R38fs change, which has now
been discounted.
The commonest mutation identified was the C948Y change
in CRB1 (nine patients, two homozygous). The two GUCY2D
variants P701S and W21R, labeled as disease associated by
Asper Ophthalmics, but possibly polymorphisms,20,23,24 were
highly prevalent in our cohort (16 and 14 alleles identified in
16 and 11 patients, respectively). Seven of the 10 patients with
the W21R change were from the Indian subcontinent. Based
on results given below the P701S or W21R variants were not
included in the analysis and, after direct sequencing, the AIPL1
R38fs allele was also eliminated from our analysis. This reduced
the detection rate significantly with one mutation identified in
28 (18.3%) of 153 patients, and two mutations identified in 18
(11.7%) of 153, giving an indication of genotype in a total of
30%.
FIGURE 1. HinpII restriction digest showing the PCR product, ho-
mozygous and heterozygous for the W21R variant in GUCY2D against
a PhiX ladder.
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Chip Results by Diagnosis
The chip results, when analyzed by diagnosis, with the poly-
morphisms and false-positive AIPL1 R38fs calls discounted,
showed that in the LCA patients, one or two mutations were
found in 27 (46%) of 59 of patients, while in the patients with
EOSRD, changes were found in 24% (Table 4).
Apex Chip Reliability. There were 3346 unidirectional
call failures (3.06%) and 259 bidirectional call failures (0.47%
i.e., 518 unidirectional calls) of the possible 109,392 allele calls
made, producing a combined value of 3.5%. A call failure is
defined as the nondetection of a signal by the chip for a
particular allele. A unidirectional failure is one strand missed,
and in a bidirectional failure neither the forward nor the re-
verse strand is detected. Bidirectional failures are the most
significant since they represent a no-call at the SNP in question.
Insertions, deletions, and splice site variants represent a total of
28% (n  96) of the 344 variants arrayed on the chip: as a
proportion of call failures; however, they account for 35%. Five
variants were associated with particularly low combined uni-
and bidirectional call failures (Table 5). The five variants on the
LCA chip with the greatest number of call failures.). This is,
however, skewed by a high unidirectional failure rate. A fairer
assessment of failure was obtained by assessing the total num-
ber of bidirectional failures, shown in Table 6.
RPE65 Sequencing. One hundred thirty-four (84%) of the
159 individuals analyzed using the chip, were also sequenced
for mutations in RPE65. There were 83 disease-associated
mutations in RPE65 arrayed on the chip. Direct sequencing of
RPE65 confirmed each of the 22,244 (83  134  2) calls
made.
We identified two novel homozygous missense mutations
(L60P, Y249C); two heterozygous mutations (889delA, E6X), of
which one mutation had been identified from the chip; and
two further heterozygous variants (IVS210 AG, D110V)
where a second change could not be found. The homozygous
and compound heterozygous sequence variants segregated in
the parents and were not found in normal control subjects. All
novel changes were assayed in panels of ethnically matched
TABLE 1. Details of the LCA and EOSRD Patient Cohort
Diagnosis
Patients
(n)
Mean Age
at Diagnosis
(y)
Mean Age at
Onset of
First Symptoms
(y)
Rod-cone dystrophy 65 5.9 2.32
Cone-rod dystrophy 29 5.5 1.5
LCA 59 1.1 0.18
TABLE 2. The Number of Disease-Associated Variants in Each Gene
Detected by the Asper Ophthalmics LCA Chip
Patients
(n)
Single
Mutation
Two
Mutations
AIPL1 16 14 2
CRB1 14 6 8
CRX 2 1 1
GUCY2D 27 17 10
RPE65 7 3 4
RPGRIP1 8 6 1
LRAT 0 0 0
MERTK 0 0 0
This version of the Asper Ophthalmics chip did not include mu-
tations in RDH12 or CEP290, which are included in the present
version of the chip. T
A
B
LE
3
.
P
o
si
ti
ve
R
es
u
lt
s
in
P
ar
en
ts
W
h
en
th
e
P
ro
b
an
d
D
N
A
W
as
U
n
av
ai
la
b
le
R
el
at
io
n
to
P
at
ie
n
t
G
en
e
E
x
o
n
N
u
cl
eo
ti
d
e
1
P
ro
te
in
1
G
en
e
E
x
o
n
N
u
cl
eo
ti
d
e
2
P
ro
te
in
2
G
en
e
E
x
o
n
N
u
cl
eo
ti
d
e
3
P
ro
te
in
3
G
en
e
E
x
o
n
N
u
cl
eo
ti
d
e
4
P
ro
te
in
4
M
o
th
er
o
f
10
27
3
A
IP
L1
3
28
6G

A
V
96
1
M
o
th
er
o
f
16
72
8
A
IP
L1
2
11
1d
el
C
R
38
fs
Fa
th
er
o
f
13
17
0
A
IP
L1
3
40
1A

T
Y
13
4F
C
R
B
1
9
28
43
G

A
C
94
8Y
Fa
th
er
o
f
13
27
8
A
IP
L1
3
40
1A

T
Y
13
4F
R
P
G
R
IP
1
16
24
35
G

A
R
81
2Q
G
U
C
Y
2
D
10
21
01
C

T
P
70
1S
G
U
C
Y
2
D
2
61
T

C
W
21
R
Fa
th
er
o
f
10
83
0
G
U
C
Y
2
D
8
17
24
C

T
P
57
5L
5686 Henderson et al. IOVS, December 2007, Vol. 48, No. 12
control subjects and were not identified. All mutations oc-
curred at positions that were conserved across several species.
CRB1 Sequencing. We confirmed each of the mutations
found on the LCA chip by direct sequencing. In one patient,
however, a C1181R homozygous mutation called by the chip
was determined on sequencing as C1181InsG, leading to a
frame shift and termination 12 codons downstream. In one
other patient, in whom a heterozygous G850S mutation was
confirmed on one allele, a second mutation, G1103R (a previ-
ously reported change that is found on the chip), was noted.
This finding represents a false-negative report from the chip. It
was reported to Asper Ophthalmics who have subsequently
redesigned primers to remedy the problem.
AIPL1 Sequencing. Sixteen patients were identified as
having mutations within the AIPL1 gene using the LCA chip.
Of these individuals, 14 had only a single allele identified. Five
patients who were identified on the chip as having a
c.111delC, p.R38fs mutation, were in fact discovered on se-
quencing to have a synonymous c.111CT, p.F37F variant
(Fig. 2). When contacted, Asper Ophthalmics attributed the
error to a “mistake in the reference file.” All other findings
highlighted by the chip were confirmed including one homozy-
gote and one compound heterozygote. No further novel mu-
tations were identified.
SNP Assay Results
One hundred ninety-two unrelated control DNA samples as
taken from the ECACC control panel were assayed for changes
in GUCY2D at position 2101CT which codes for the P701S
change. The heterozygous CT change was found in 12/189
samples (6.3%). No homozygous T/T calls were found. The
same heterozygous change was found in 10% of the LCA/
EOSRD panel as identified by the LCA chip where, again, there
were no homozygotes identified. There is no significant differ-
ence in the frequency of the P701S allele (one-tailed Fisher
exact test; P  0.1) between the LCA/EOSRD populations and
the normal population. If the heterozygous P701S allele is in
Hardy-Weinberg equilibrium and is fully penetrant, one would
expect the frequency of LCA/EOSRD to be an order of magni-
tude greater than is actually seen within the normal popula-
tion.
It was found, by HinpII restriction digest assessing the
prevalence of the W21R change, that 10 (16.6%) of 60 Asian
control subjects had a heterozygous change at this position,
whereas in the British ECACC panel, the heterozygous change
was identified in 8 (8.3%) of 96, thus excluding it as a disease-
associated variant in either population compared to 14 of 159
seen in the EOSRD panel (one-tailed Fisher exact test; P 
0.27). Our hypothesis that the W21R change is more prevalent
within patients from the Indian subcontinent, based on the
finding that 7 of 10 patients identified with this change on the
chip were either from Pakistan, India, or Bangladesh, is thus
rejected (one-tailed Fisher exact test; P  0.09).
DISCUSSION
Previous validations of the assay have been performed by the
designer and manufacturer of the chip23,27 and subsequently in
a smaller cohort by Yzer et al.25 Our study presents an inde-
pendent analysis of the chip in a large cohort of patients with
LCA and EOSRD, in whom 90% of the phenotyping has been
performed by two individuals. Both disease-causing alleles
were identified in 11.7% of patients, and one disease-associated
allele in a further 19.6%. Overall, the likely causative gene was
identified in a third of patients. The chip was originally de-
signed specifically for LCA patients and, of the 59 LCA patients,
one mutation was identified in 31% and two mutations in 15%,
giving a combined value of 46%.
We validated the array for RPE65 by direct sequencing of
the entire coding region and found the chip to have a sensi-
tivity of 100% for variants arrayed on the chip. Four novel
mutations were identified by direct sequencing. These muta-
tions were not found in 192 normal Caucasian and 48 Asian
control subjects. We identified two missense mutations,
p.L60P and p.Y249C; one single-base deletion, c.889delA; and
a nonsense mutation, p.E6X. Leucine at amino acid position 60
TABLE 4. Number of Mutations Identified by the Apex Chip for Each Diagnosis
Gene
Cone-Rod (n  29) Rod-Cone (n  65) LCA (n  59)
2
Mutations
1
Mutation
2
Mutations
1
Mutation
2
Mutations
1
Mutation
AIPL1 0 0 1 6 1 3
CRB1 2 0 2 2 4 4
CRX 1 0 0 0 0 1
RPE65 1 0 2 1 1 1
GUCY2D 0 0 0 0 2 7
RPGR1P1 0 0 0 5 1 2
Total 4 (14%) 0 (0%) 5 (8%) 14 (22%) 9 (15%) 18 (31%)
See Supplementary Table S1 for full results (online at http://www.iovs.org/cgi/content/full/48/12/5684/DC1).
TABLE 5. The Five Variants on the LCA Chip with the Greatest Number of Call Failures
Gene Exon Nucleotide Protein
Call Failures
(n) % of Total Calls*
RPE65 12 1307GT G436V 155 49
RPGRIP1 IVS6-17 907-17delTAA
52–99 duplicate
SPLICE
-ins 16
164 52
GUCY2D 2 48 bp AA 123 39
GUCY2D 2 2TA MIK 113 36
CRB1 11 4123delG FS 107 34
* n  318.
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and tyrosine at position 249 are highly conserved, suggesting
that they form part of a functional domain of the protein. The
other two mutations, p.E6X and c.889delA, result in premature
termination of RPE65 and are likely to be pathogenic.
While identifying a second CRB1 disease-associated allele in
those patients in whom a single mutation was found on the
chip, discrepancies were noted: one false-negative result
(G1103R) on the chip, that was confirmed on repeat testing by
Asper Ophthalmics and one sequence variant (C1181InsG) at
an SNP (C1181R) found on the chip. This latter finding is
interesting, as it demonstrates that the chip has a limited
capacity to identify novel variants at previously identified SNP
sites. The result reported by Asper Ophthalmics was a homozy-
gous C1181R change, though they did indicate that the reverse
strand had failed. This finding has been reported recently when
using this technique for detecting mutations in patients with
Usher syndrome.28
In addition, our sequencing results of AIPL1 identified that
one particular call made in five patients—c.111delC, p.R38fs—
was in fact not detecting the correct SNP. Asper Ophthalmics
have subsequently redesigned their primers. A single mutation
highlighted by the chip allowed us to find a second change in
only 4 of 11 possible patients when screening AIPL1 and
CRB1. Potential reasons for this include the commonly cited
difficulties that PCR-based techniques have in detecting dele-
tions or indeed that other SNPs called as mutations are possibly
rare polymorphisms, and hence a second change would not be
expected. Yzer et al.25 demonstrated that the AIPL1 p.V96I
was present in the heterozygous form in 11 of 186 control
subjects and was therefore not included in their analysis (this
would remove a further two single alleles from our analysis).
Two previous studies have reported the results of using the
Asper Biotech chip in screening for mutations in LCA. Zernant
et al.23 identified mutations in 20.3% to 23.8% of the total
number of alleles in their cohort. Yzer et al.25 reported that
24% (14/58) of their subjects had homozygous or compound
heterozygous changes and in a further six subjects, a single
mutant allele was identified. In the present study, investigating
both LCA and EOSRD patients, we identified a mutation in both
alleles in only 11.7% of subjects but in a further 18.3% of subjects
identified, a single heterozygous disease-associated allele.
The results from these studies are not easily compared as
other studies23,25 have confined their analysis to LCA and have
used earlier versions of the chip which included fewer se-
quence variants. Furthermore, Zernant et al.23 reported only
the number of alleles identified and not the proportion of
subjects in whom both disease-causing alleles were identified.
Nonetheless, some comparisons can be made: It appears that if
one discounts the presence of two alleles in two different genes,
then 22 (10%) patients in their cohort were identified by the chip
as being homozygotes or compound heterozygotes. Our findings
suggest a higher number (9.5% of EOSRD and 15% of LCA pa-
tients) which is likely to be consistent with a greater number of
mutations arrayed on the newer chip. The smaller study of LCA
Yzer et al.25, however, detected a greater number (24%) of sub-
jects with homozygous or compound heterozygous changes.
A like-for-like comparison using the 147 probands in our
study and including the GUCY2D P701S and W21R alleles
(though not the AIPL1 R38fs allele) as was done by Zernant et
al.,23 reveals a screening efficiency of 94 (31.9%) of 294 pos-
sible alleles compared with the 20% to 24% efficiency identi-
fied by Zernant et al. A more accurate comparison using only
the LCA patients in our cohort and including both P701S and
W21R polymorphisms revealed a screening efficiency of 39%.
In conclusion, it appears that the screening efficiency, with
the updated version of the chip was greater in our cohort (despite
our using a less stringently selected group of patients than that
used by Zernant et al.,23) but less than that which Yzer et al.25
reported, even when only the LCA patients are analyzed.
An important difference between our study and that of
Zernant et al.23 is the inclusion of the GUCY2D P701S change.
They refer to this variant as a causative mutation in their
analysis, together with a compound heterozygous change,
p.H945R, which they identified in an Iranian family and which
segregated with disease. It has been demonstrated that the
P701S change is present in 6.3% of the normal British blood
donor population and in a similar proportion of the EOSRD
cohort. This finding, and that the encoded amino acid change
FIGURE 2. Sequence file for 111CT SNP in AIPL1, miscalled as
111delC by the Apex chip.
TABLE 6. The SNPs with the Greatest Number of Bidirectional Call Failures
Gene Exon Nucleotide Protein
Number of
Bidirectional
Failures
% as a Proportion
of 159 Subjects
GUCY2D 2 del 14bp 226–239 FS 12 7.5
GUCY2D 3 974TC L325P 11 7.0
GUCY2D 15 2899 del C FS 10 6.0
GUCY2D 15 2927GT R976L 9 5.6
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(H945R) is likely to represent a conservative change (both
histidine and arginine are basic amino acids), means that it is
unlikely that this sequence variant is pathogenic. The argument
that was used contended that the P701S change causes disease
in some populations but not in others. This notion seems
unlikely, especially when considering our unaffected parent
who had no signs of retinal disease but was carrying heterozy-
gous variants in AIPL1 (Y134F), RPGRIP1 (R812Q), and
GUCY2D (P701S and W21R). Although no unaffected homozy-
gotes for the P701S change were identified in our cohort, we
assayed only 192 control subjects, and the likelihood of iden-
tifying a homozygote in this number is low.
Zernant et al.23 reported that a third allele was present in 22
(7.3%) of 300 of their cohort and suggested that some of these
variants represented modifier alleles. If the P701S allele is
included in the analysis of our study, then three alleles in five
subjects (3%) were identified, two of whom were parents of
probands and the genotype of the affected child was unknown.
The reasons for the differences between the two studies are
unclear.
We have demonstrated that that the chip is a sensitive
technology with a low call failure rate. For example, we have
shown that the chip has 100% sensitivity for detection of
known mutations in RPE65 when compared with the direct
sequencing. It provides an excellent first-pass screening in
molecular genetic diagnosis in LCA. In our study, the use of the
LCA chip in a population of patients with LCA or EOSRD
resulted in the detection of multiple disease-causing alleles in
12% of patients and one allele in 20%. Several anomalies be-
tween direct sequencing and the chip results were demon-
strated. These included false-positive results in the case of the
11 cited AIPL1 c.111delC, p.R38fs changes; a false-negative in
the instance of the nondetected heterozygous CRB1 G1103R
mutation; and a sequence variant, C1181InsG, at the CRB1
C1181R site.
We have demonstrated that P701S and W21R in GUCY2D
are as prevalent in the normal population as they are in the
LCA/EOSRD population, making the case that it is unlikely that
they are pathogenic sequence variants.
Overall, the Apex chip technology provides a quick and
cost-effective means of obtaining a genotype in patients with
EOSRD or LCA, for whom it was originally designed. Although
false-positive and -negative results occurred and certain SNPs
had a relatively high call failure rate, our experience suggests
that the problems are no worse than the difficulties that can be
experienced with direct sequencing. Improvements in technol-
ogy and the inclusion of new mutations and additional genes on
the chip will increase the proportion of patients in whom a
molecular diagnosis can be made by using this technique. These
advances will improve genetic counseling in affected families and
help identify patients who may benefit from future clinical trials
for LCA and early-onset retinal dystrophies.
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